- Dossier preparation manuals
- <u>Q&A</u>
- Create support request
- <u>IUCLID user community</u>
- Additional information
- Video tutorials

SuperUser EPA/ORD/CCTE/SCDCD

- User Settings
- Logout
- Dashboard
- Substances
- 1,3-Cyclohexanedimethanamine, N1,N3...

Filtered aggr_1

c8636a42-2122-4587-b222-83066cf76852

View Dossiers Validate

- Export to i6z
- Extract to dataset
- Create component PDF/RTF
- Create document PDF/RTF
- Compare
- Generate report
- Dissemination preview

Type at least 3 characters

REACH Complete

1,3-Cyclohexanedimethanamine, N1,N3-bis(2-methylpropylidene)-

- 1 General information
 - 3
- 2 Classification & Labelling and PBT assessment
- 3 Manufacture, use and exposure
- 4 Physical and chemical properties

24

5 Environmental fate and pathways

3

6 Ecotoxicological information

5

7 Toxicological information

18

- o 8c6c8320-84ed-41ae-8f05-3972e6b76ce9
- 7.1 Toxicokinetics, metabolism and distribution

1 o 7.2 Acute Toxicity 3 o 7.3 Irritation / corrosion 4 o 7.4 Sensitisation 2 o 7.5 Repeated dose toxicity 3 ■ 7.5.1 Repeated dose toxicity: oral 1 ■ 12d50ae1-2a8d-4fe4-a3eb-b2c6dd6f32ee ■ 7.5.2 Repeated dose toxicity: inhalation 1 ■ 7.5.3 Repeated dose toxicity: dermal
 7.5.4 Repeated dose toxicity: other routes 7.6 Genetic toxicity 3 7.7 Carcinogenicity 7.8 Toxicity to reproduction 1 7.9 Specific investigations 7.10 Exposure related observations in humans 7.11 Toxic effects on livestock and pets 7.12 Additional toxicological information 8 Analytical methods 9 Residues in food and feedingstuffs 10 Effectiveness against target organisms 11 Guidance on safe use 12 Literature search 13 Assessment reports 14 Information requirements Inherited templates
UUID 12d50ae1-2a8d-4fe4-a3eb-b2c6dd6f32ee ☐ Hide empty fields • Compare Document
Administrative data Data source Materials and methods Results and discussion Overall remarks, attachments
Applicant's summary and conclusion
Administrative data
Endpoint short-term repeated dose toxicity: oral

Type of information experimental study
Adequacy of study key study
Robust study summary
Used for classification
Used for SDS
Study period
Reliability 1 (reliable without restriction)
Rationale for reliability incl. deficiencies
Data waiving
Justification for data waiving
Justification for type of information
Attached justification
Attached justification Reason / purpose Actions
Cross-reference
Reason / purpose for cross-reference Related information Remarks Actions
Data source
Reference
• study report Unnamed 2011 2011-10-28
Data access
Data protection claimed
Materials and methods
Test guideline
Qualifier Guideline Version / remarks Deviations Actions 1 Qualifier according to guideline
Guideline OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Version / remarks Deviations
no 2
Qualifier
according to guideline Guideline
EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
Version / remarks Deviations

no 3 Qualifier according to guideline Guideline other: Version / remarks Deviations no
Principles of method if other than guideline
GLP compliance yes (incl. QA statement)
Limit test no
Test material
Test material information
• Unnamed Unnamed Incorez 397 Unnamed (2-methylpropylidene)[(3-{[(2-methylpropylidene)amino]methyl}cyclohexyl)methyl]amine EC 619-764-7 173904-11-5
Additional test material information
Specific details on test material used for the study
Specific details on test material used for the study (confidential)
Test animals
Species rat
Strain other:
Details on species / strain selection
Sex male/female
Details on test animals or test system and environmental conditions
Administration / exposure
Route of administration oral: gavage
Details on route of administration
Vehicle
Details on oral exposure
Analytical verification of doses or concentrations
Details on analytical verification of doses or concentrations
Duration of treatment / exposure

Frequency of treatment
Doses / concentrations
Dose / conc. Remarks Actions
No. of animals per sex per dose
Control animals
Details on study design
Positive control
Examinations
Observations and examinations performed and frequency
Sacrifice and pathology
Optional endpoint(s)
Other examinations
Statistics
Any other information on materials and methods incl. tables
Results and discussion
Results of examinations
Clinical signs
Description (incidence and severity)
Mortality
Description (incidence)
Body weight and weight changes
Description (incidence and severity)
Food consumption and compound intake (if feeding study)
Description (incidence and severity)
Food efficiency
Description (incidence and severity)
Water consumption and compound intake (if drinking water study)
Description (incidence and severity)
Ophthalmological findings
Description (incidence and severity)
Haematological findings

Description (incidence and severity)
Clinical biochemistry findings
Description (incidence and severity)
Endocrine findings
Description (incidence and severity)
Urinalysis findings
Description (incidence and severity)
Behaviour (functional findings)
Description (incidence and severity)
Immunological findings
Description (incidence and severity)
Organ weight findings including organ / body weight ratios
Description (incidence and severity)
Gross pathological findings
Description (incidence and severity)
Neuropathological findings
Description (incidence and severity)
Histopathological findings: non-neoplastic
Description (incidence and severity)
Histopathological findings: neoplastic
Description (incidence and severity)
Other effects
Description (incidence and severity)
Details on results
Effect levels
Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions 1 Key result Dose descriptor NOAEL Effect level 609 mg/kg bw/day (actual dose received) Based on test mat. Sex male/female Basis for effect level • other:
Remarks on result

Target system / organ toxicity
Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions 1
Key result
Critical effects observed
not specified
Lowest effective dose / conc.
System Organ
Treatment related
Dose response relationship
Relevant for humans
Any other information on results incl. tables
Overall remarks, attachments
Overall remarks
Attachments
Type Attached (confidential) document Attached (sanitised) documents for publication Remarks Actions
Illustration (picture/graph)
Applicant's summary and conclusion
Conclusions
Executive summary
TOP
 Dashboard
• Substances
Mixtures / Products
• Articles
Categories
Toolbox
TemplateManage Reports
Inventory manager
• Contact
Legal entity
• Sites
Reference substance

User management

Test materialLiterature reference

- User Settings
- Users
- Roles

About IUCLID

- About
- Help